40 likes | 190 Views
PD-1/PD-L1 임상개발 비교표. October, 2014. Clinical Trials for NSCLC (P3 Only). *+Gemcitabine + cisplatin + carboplatin + paclitaxel + pemetrexed (investigators’ choice chemo) ** carboplatin + paclitaxel + pemetrexed
E N D
PD-1/PD-L1 임상개발 비교표 October, 2014
Clinical Trials for NSCLC (P3 Only) *+Gemcitabine + cisplatin + carboplatin + paclitaxel + pemetrexed (investigators’ choice chemo) ** carboplatin + paclitaxel + pemetrexed *** (pemetrexed+ carboplatin) or (pemetrexed + cisplatin) or (gemcitabine + carboplatin) or (gemcitabine + cisplatin)
Clinical Trials for Melanoma (P3/P2 Only) * Dacarbazien or (carboplatin + paclitaxel) ** dabrafenib(BRAFT inhibitor) + trametinib(MEK inhibitor) *** (carboplatin + paclitaxel) or paclitaxel or dacabazine or temozolomide